Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Clinical Research
  • Published:

Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study

Prostate Cancer and Prostatic Diseases volume 26, pages 410–414 (2023)Cite this article

Subjects

Abstract

Background

The Rezum system is one of the latest minimally invasive surgical treatments for benign prostatic hyperplasia.

Methods

We retrospectively reviewed all patients who underwent the Rezum treatment in seven different Italian institutions. A successful urinary outcome was defined as: ≥50% improvement in the IPSS <7, improvement in peak flow ≥50% and/or more than 15 ml/s, ≥1-point improvement in the QoL questionnaire and in the absence of perioperative major complications (AUR, transfusion) or postoperative incontinence. A successful sexual outcome was defined as postoperative (latest follow up consultation) antegrade ejaculation or no variation in ejaculatory function and an increase, or stability or max 1 class reduction, in IIEF-5.

Results

262 patients were enrolled with a follow-up period of 11 months (IQR 5–15). No early or late serious adverse events (Clavien III–IV) occurred. Early complications occurred in 39.3% of cases, with 4 cases of clot retention and one case of blood transfusion. Urge incontinence was reported by 6 patients (2.2%). A treatment failure requiring re-intervention occurred in 4 cases (1.5%). The preoperative antegrade ejaculation rate was 56.5%, and after the procedure it increased to 78.2%. The increase of ≥1-point in the QoL was achieved in 92.7% of the cases. Optimal urinary and sexual outcomes were achieved in 52.9% and 87.8%, respectively.

Conclusions

In our series, water vapor intraprostatic injections seem to be an effective and safe procedure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127:722–8.

    Article  PubMed  Google Scholar 

  2. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Edn. presented at the EAU Annual Congress Amsterdam. Arnhem, The Netherlands: EAU Guidelines Office; 2020. http://uroweb.org/guidelines/compilations-of-all-guidelines/ ISBN 978-94-92671-07-3

    Google Scholar 

  3. Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68:418–25. https://doi.org/10.1016/j.eururo.2014.11.006

    Article  PubMed  Google Scholar 

  4. Gu C, Zhou N, Gurung P, Kou Y, Luo Y, Wang Y, et al. Lasers versus bipolar technology in the transurethral treatment of benign prostatic enlargement: a systematic review and meta-analysis of comparative studies. World J Urol. 2020;38:907–18.

    Article  PubMed  Google Scholar 

  5. Manfredi C, Arcaniolo D, Spatafora P, Crocerossa F, Fusco F, Verze P, et al. Emerging minimally invasive transurethral treatments for benign prostatic hyperplasia: a systematic review with meta-analysis of functional outcomes and description of complications. Minerva Urol Nephrol. 2021. https://doi.org/10.23736/S2724-6051.21.04530-4. Epub ahead of print

  6. Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D, et al. New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes. Eur Urol Open Sci. 2021;33:28–41. https://doi.org/10.1016/j.euros.2021.08.009

    Article  PubMed  PubMed Central  Google Scholar 

  7. McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin R, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021;206:715–24.

    Article  PubMed  Google Scholar 

  8. Siena G, Cindolo L, Ferrari G, Maruzzi D, Fasolis G, Condorelli SV, et al. Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol. 2021;39:3875–80. https://doi.org/10.1007/s00345-021-03642-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Franco G, De Nunzio C, Federico G, Laurenti C. Evaluation of sexual activity after prostatic surgery for benign prostatic hyperplasia assessed by pre-operative and post-operative questionnaire. Minerva Urol Nefrol. 2005;57:331–4.

    CAS  PubMed  Google Scholar 

  10. Zheng J, Pan J, Qin Y, Huang J, Luo Y, Gao X, et al. Role for intravesical prostatic protrusion in lower urinary tract symptom: a fluid structural interaction analysis study. BMC Urol. 2015;15:86 https://doi.org/10.1186/s12894-015-0081-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cindolo L, Campobasso D, Ferrari G, Cicione A, De Nunzio C. Expanding indications for Rezum procedure. Urol Video J. 2022;14:100154.

    Article  Google Scholar 

  12. Cindolo L, Ferrari R, Rabito S, Siena G, Spatafora P, Ferrari G. Rezum procedure with Exime® stent: a step forward to micro-invasiveness. Minerva Urol Nephrol. 2021;73:273–5.

    Article  PubMed  Google Scholar 

  13. Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol. 2011;29:205–10.

    Article  PubMed  Google Scholar 

  14. Javle P, Jenkins SA, Machin DG, Parsons KF. Grading of benign prostatic obstruction can predict the outcome of Transurethral Prostatectomy. J Urol. 1998;160:1713–17.

    Article  CAS  PubMed  Google Scholar 

  15. McVary KT, El-Arabi A, Roehrborn C. Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia. Sex Med. 2021;9:100454.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cocci A, Bocchino A, Cito G, De Lisa A, Russo G, Lo Giudice A, et al. Role of Rezum in the treatment of benign prostate hyperplasia: A review of the literature. Turk J Urol. 2021;47:452–60. https://doi.org/10.5152/tud.2021.21128

    Article  PubMed  PubMed Central  Google Scholar 

  17. Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezum system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159–68.

    PubMed  PubMed Central  Google Scholar 

  18. Mollengarden D, Goldberg K, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis. 2018;21:379–85.

    Article  PubMed  Google Scholar 

  19. McVary KT, Rogers T, Roehrborn CG. Rezum Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology 2019;126:171–9.

    Article  PubMed  Google Scholar 

  20. Johnston MJ, Noureldin M, Abdelmotagly Y, Paramore L, Gehring T, Nedas TG, et al. Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int. 2020;126:557–8.

    Article  PubMed  Google Scholar 

  21. Bole R, Gopalakrishna A, Kuang R, Alamiri J, Yang DY, Helo S, et al. Comparative postoperative outcomes of rezum prostate ablation in patients with large versus small glands. J Endourol. 2020;34:778–81.

    Article  PubMed  Google Scholar 

  22. Garden EB, Shukla D, Ravivarapu KT, Kaplan SA, Reddy AK, Small AC, et al. Rezum therapy for patients with large prostates (≥80 g): initial clinical experience and postoperative outcomes. World J Urol. 2021;39:3041–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ines M, Babar M, Singh S, Iqbal N, Ciatto M. Real-world evidence with The Rezūm System: a retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes. Prostate 2021;81:956–70.

    Article  CAS  PubMed  Google Scholar 

  24. Eredics K, Wehrberger C, Henning A, Sevcenco S, Marszalek M, Rauchenwald M et al. Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency. Prostate Cancer Prostatic Dis. 2021. https://doi.org/10.1038/s41391-021-00462-w. Online ahead of print.

  25. Fernández-Guzmán E, Asensio Matas A, Capape Poves V, Rioja Zuazu J, Garrido Abad P, Martínez-Salamanca JI, et al. Preliminary results of a national multicenter study on the treatment of LUTS secondary to benign prostatic hyperplasia using the Rezūm® steam system. Actas Urol Esp. 2022;46:310–6.

    Article  PubMed  Google Scholar 

  26. Whiting D, Noureldin M, Abdelmotagly Y, Johnston MJ, Brittain J, Rajkumar G, et al. Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia. Eur Urol Open Sci. 2022;39:72–8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Large, Multi-Center, Prospective Registry of Rezūm Water Vapor Therapy for Benign Prostatic Hyperplasia. Urology. 2022:S0090–4295(22)00142-X. https://doi.org/10.1016/j.urology.2022.02.001. Online ahead of print.

  28. Aladesuru O, Amankwah K, Elterman D, Zorn KC, Bhojani N, Teet A et al. Pilot Study of “Less is More” Rezum for Treatment of BPH. Urology. 2022:S0090–4295(22)00094-2. https://doi.org/10.1016/j.urology.2022.01.039. Online ahead of print.

  29. Sokolakis I, Pyrgidis N, Russo GI, Sountoulides P, Hatzichristodoulou G. Preserving Ejaculation: A Guide Through the Landscape of Interventional and Surgical Options for Benign Prostatic Obstruction. Eur Urol Focus. 2022:S2405–4569(22)00062-1. https://doi.org/10.1016/j.euf.2022.03.008. Online ahead of print.

Download references

Author information

Author notes

  1. These authors contributed equally: Davide Campobasso, Giampaolo Siena.

Authors and Affiliations

  1. Department of Urology, University Hospital of Parma/Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

    Davide Campobasso

  2. Department of Urology, Careggi Hospital, University of Florence, “San Luca Nuovo”, Florence, Italy

    Giampaolo Siena

  3. Medical Statistics Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy

    Paolo Chiodini

  4. Department of Urology, Levante Ligure Hospital, La Spezia, Italy

    Enrico Conti

  5. Department of Urology, Desio Hospital, Desio, Italy

    Francesco Franzoso

  6. Department of Urology, “S. Maria Degli Angeli” Hospital, Pordenone, Italy

    Daniele Maruzzi

  7. Department of Urology, “SS. Annunziata” Hospital, Taranto, Italy

    Evangelista Martinelli

  8. Department of Urology, “Michele e Pietro Ferrero” Hospital, Alba-Bra, Italy

    Francesco Varvello

  9. Department of Urology, “Sant’Andrea” Hospital, Sapienza University, Roma, Italy

    Cosimo De Nunzio

  10. Division of Urology, Virginia Commonwealth University (VCU) Health, Richmond, VA, USA

    Riccardo Autorino

  11. Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

    Bhaskar Kumar Somani

  12. Department of Urology, “Hesperia Hospital”, and CURE Group, Modena, Italy

    Giovanni Ferrari & Luca Cindolo

  13. Department of Urology, “Villa Stuart” Private Hospital, Rome, Italy

    Luca Cindolo

Authors
  1. Davide Campobasso
    View author publications

    Search author on:PubMed Google Scholar

  2. Giampaolo Siena
    View author publications

    Search author on:PubMed Google Scholar

  3. Paolo Chiodini
    View author publications

    Search author on:PubMed Google Scholar

  4. Enrico Conti
    View author publications

    Search author on:PubMed Google Scholar

  5. Francesco Franzoso
    View author publications

    Search author on:PubMed Google Scholar

  6. Daniele Maruzzi
    View author publications

    Search author on:PubMed Google Scholar

  7. Evangelista Martinelli
    View author publications

    Search author on:PubMed Google Scholar

  8. Francesco Varvello
    View author publications

    Search author on:PubMed Google Scholar

  9. Cosimo De Nunzio
    View author publications

    Search author on:PubMed Google Scholar

  10. Riccardo Autorino
    View author publications

    Search author on:PubMed Google Scholar

  11. Bhaskar Kumar Somani
    View author publications

    Search author on:PubMed Google Scholar

  12. Giovanni Ferrari
    View author publications

    Search author on:PubMed Google Scholar

  13. Luca Cindolo
    View author publications

    Search author on:PubMed Google Scholar

Contributions

DC and GS Conceptualization, Methodology, Writing-Original Draft. PC Methodology, Formal analysis. EC, FF, DM, EM, FV Data Curation. CDN, RA Writing-Review & Editing. BKS and GF Supervision. LC Conceptualization, Methodology, Formal analysis, Writing-Review & Editing.

Corresponding author

Correspondence to Davide Campobasso.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Campobasso, D., Siena, G., Chiodini, P. et al. Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study. Prostate Cancer Prostatic Dis 26, 410–414 (2023). https://doi.org/10.1038/s41391-022-00587-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41391-022-00587-6

This article is cited by

Search

Advanced search

Quick links